What is the Growth Outlook for Non Invasive Prenatal Testing Market?

Posted by Johnny on September 2nd, 2022

Non-Invasive Prenatal Testing (NIPT) Market-By Region

The major factors driving the growth of Non Invasive Prenatal Testing market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies) 

[144 Pages Report] The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

Report Scope and Market Segmentation:

Report Metric

Details

Market Size Available for Years

2017–2024

Base Year Considered

2018

Forecast Period

2019–2024

Forecast Units

Value (USD Billion)

Segments Covered

Product and Service, Application, and Region

Geographies Covered

North America (US and Canada), Europe (Germany, UK, France, and RoE), Asia, and the Rest of the World

Companies Covered

Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

 

The services segment is expected to grow at the highest CAGR during the forecast period.

On the basis of product and service, the NIPT market is segmented into products and services. The services segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rising incidence of genetic disorders, increasing focus on prenatal screening, and government initiatives to provide prenatal testing services are contributing to the growth of this market.

The trisomy segment accounted for the largest share of the market

On the basis of application, the NIPT market is segmented into trisomy, microdeletion syndrome, and other applications. The trisomy segment accounted for the largest share of the non-invasive prenatal testing market. This segment is also expected to register the highest CAGR during the forecast period.

North America dominated the NIPT market

Growth in the North American market is supported by the presence of a better reimbursement structure and a favorable funding scenario for research activities, rising awareness about NIPT, and the increasing demand for the early detection of birth defects in this region.

Illumina, Inc. (US)

Illumina is one of the major players in the non-invasive prenatal testing market. The company offers a range of highly interconnected products related to sequencing, genotyping, gene expression, and molecular diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and support services which further strengthen its market position.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

Like it? Share it!


Johnny

About the Author

Johnny
Joined: July 19th, 2022
Articles Posted: 122

More by this author